Clinical trial
Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell…
NCT00284778 · University Hospital, Limoges, Other · Completed
Key facts
| NCT number | NCT00284778 |
|---|---|
| Title | Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer |
| Official title | A Randomized Cost-minimization Trial Comparing Pemetrexed (Alimta®) Versus Docetaxel (Taxotere®) as Second Line Treatment in Advanced Non Small Cell Lung Cancer (NSCLC): Study 05-06 of Groupe Français de Pneumo-Cancérologie (GFPC). |
| Lead sponsor | University Hospital, Limoges, Other |
| Collaborators | Groupe Francais De Pneumo-Cancerologie |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | Alimta®, Taxotere® |
| Enrollment | 150 |
| Start date | Feb 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Feb 1, 2006 |
| Last update posted | Jul 24, 2025 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: